Vifor Pharma UK, which specialises in the treatment of anaemia, has partnered with charity Crohn’s and Colitis UK.
As a 2013 gold level corporate supporter of the charity, Vifor Pharma will help it to raise awareness of the risk of anaemia linked to inflammatory bowel disease (IBD).
Up to 90% of people with IBD, of which Crohn’s disease and ulcerative colitis are major forms, may suffer from iron deficiency leading to anaemia.
A range of treatments exist for iron deficiency, from dietary management to oral or intravenous iron supplements and blood transfusions.
Vifor Pharma specialises in intravenous iron therapies, with UK products including Ferinject and Venofer.
IBD affects some 240,000 people in the UK, and its symptoms – including fatigue, stomach pain and diarrhoea – are often acerbated by anaemia, which causes severe weakness.
Derek Williams, General Manager of Vifor Pharma UK, commented: “Our vision, as an organisation, is to ensure that we are always getting it right for people with iron deficiency. As proud corporate supporters of Crohn’s and Colitis UK, Vifor Pharma will support the charity throughout 2013 to help fund projects that will help to make a positive impact on the large number of people that suffer with anaemia.”
“We are delighted that Vifor Pharma UK has chosen to support us throughout 2013,” said Suzi Clark, Director of Marketing and Fundraising at Crohn’s and Colitis UK. “Without the help of such supporters, we would not be able to undertake the work that we do, endeavouring to ensure that people with IBD are able to access information and support to help achieve the best possible quality of life.”
Vifor Pharma, based in Switzerland, is a subsidiary of Galenica and offers a diversified portfolio of prescription and OTC medicines for iron deficiency.